Biotech Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Atherectomy
New Device for Clearing Blocked Arteries in the Legs Receives FDA Clearance for Peripheral Use - Procedures Performed Across the US Within First 48 Hours
October 8th, 2007
Cardiovascular Systems, Inc. (CSI) announced that the U.S. Food and Drug Administration (FDA) has cleared the use of the Diamondback 360(TM) Orbital Atherectomy System (OAS) for removing plaque blockages in the legs (peripherals) and restoring blood flow. The device offers a promising new alternative for treating complex diffuse disease for patients suffering from Peripheral Arterial Disease PAD. The clearance follows the successful completion of a rigorous clinical study involving 124 patients, which demonstrated dramatic plaque reduction in leg arteries with lasting results. The OASIS trial exceeded the FDA's Objective Performance Criteria (OPC) on multiple key...
Source: Biotech Business Week (2007-10-08)
|
